IMCR Insider Trading
Insider Ownership Percentage: 10.40%
Insider Buying (Last 12 Months): $23,994,085.36
Insider Selling (Last 12 Months): $0.00
Immunocore Share Price & Price History
Current Price: $30.39
Price Change: ▲ Price Increase of +0.031 (0.10%)
As of 04/28/2025 10:30 AM ET
Immunocore Insider Trading History
Immunocore Institutional Trading History
Data available starting January 2016
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Read More on Immunocore
Today's Range
Now: $30.39
52 Week Range
Now: $30.39
Volume
251,246 shs
Average Volume
436,350 shs
Market Capitalization
$1.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.75
Who are the company insiders with the largest holdings of Immunocore?
Who are the major institutional investors of Immunocore?
Which major investors are selling Immunocore stock?
During the last quarter, IMCR stock was sold by these institutional investors:
- Exchange Traded Concepts LLC
Which major investors are buying Immunocore stock?
In the previous quarter, IMCR stock was acquired by institutional investors including:
- GAMMA Investing LLC
- Hennion & Walsh Asset Management Inc.
- Oppenheimer Asset Management Inc.